Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period
- 31 January 2008
- journal article
- research article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 58 (1), 125-135
- https://doi.org/10.1016/j.jaad.2007.09.018
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Cost-effectiveness data on biologics neededNature Biotechnology, 2005
- Strategy to manage the treatment of severe psoriasis: considerations of efficacy, safety and costExpert Opinion on Pharmacotherapy, 2003
- Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasisBritish Journal of Dermatology, 2003
- Validity and reliability of patient reported outcomes used in Psoriasis: results from two randomized clinical trialsHealth and Quality of Life Outcomes, 2003
- The Suitability of Quality-of-Life Questionnaires for Psoriasis ResearchArchives of Dermatology, 2002
- Health-related Quality of Life in Patients with Psoriasis and Atopic Dermatitis Measured with SF-36, DLQI and a Subjective Measure of Disease ActivityActa Dermato-Venereologica, 2000
- Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQIBritish Journal of Dermatology, 1999
- Psoriasis causes as much disability as other major medical diseasesJournal of the American Academy of Dermatology, 1999
- Quality of life assessments in dermatologySeminars in Cutaneous Medicine and Surgery, 1998
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994